Drug addiction unveils a repressive methylation ceiling in EZH2-mutant lymphoma

Nat Chem Biol. 2023 Sep;19(9):1105-1115. doi: 10.1038/s41589-023-01299-1. Epub 2023 Mar 27.

Abstract

Drug addiction, a phenomenon where cancer cells paradoxically depend on continuous drug treatment for survival, has uncovered cell signaling mechanisms and cancer codependencies. Here we discover mutations that confer drug addiction to inhibitors of the transcriptional repressor polycomb repressive complex 2 (PRC2) in diffuse large B-cell lymphoma. Drug addiction is mediated by hypermorphic mutations in the CXC domain of the catalytic subunit EZH2, which maintain H3K27me3 levels even in the presence of PRC2 inhibitors. Discontinuation of inhibitor treatment leads to overspreading of H3K27me3, surpassing a repressive methylation ceiling compatible with lymphoma cell survival. Exploiting this vulnerability, we show that inhibition of SETD2 similarly induces the spread of H3K27me3 and blocks lymphoma growth. Collectively, our findings demonstrate that constraints on chromatin landscapes can yield biphasic dependencies in epigenetic signaling in cancer cells. More broadly, we highlight how approaches to identify drug addiction mutations can be leveraged to discover cancer vulnerabilities.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Enhancer of Zeste Homolog 2 Protein / genetics
  • Histones / metabolism
  • Humans
  • Lymphoma* / genetics
  • Methylation
  • Neoplasms* / genetics
  • Polycomb Repressive Complex 2 / genetics
  • Polycomb Repressive Complex 2 / metabolism

Substances

  • Enhancer of Zeste Homolog 2 Protein
  • EZH2 protein, human
  • Histones
  • Polycomb Repressive Complex 2